Sodium hyaluronate injection with cell repairing function as well as preparation method and application of sodium hyaluronate injection
Through injections of sodium hyaluronate, tranexamic acid and phosphate buffer, the cell damage caused by skin aging and ultraviolet radiation is solved, and the cell viability and repair ability is significantly improved, and the skin aging process is delayed.
Patent Information
- Application Number
- CN202411033577.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-08
AI Technical Summary
The cellular damage caused by skin aging and ultraviolet radiation is difficult to effectively solve in the prior art, especially the lack of methods to supplement hyaluronic acid in the skin and reduce inflammatory responses.
Provides an injection consisting of sodium hyaluronate, tranexamic acid and phosphate buffer prepared by humid heat sterilization, optimized pH and osmotic pressure range for reducing the damage to cells by UV radiation and promoting inflammatory cells. Repair.
It significantly improves cell viability, reduces the damage to the skin by ultraviolet radiation and inflammation, enhances the repair ability of cells, and delays the skin aging process.
Smart Images

Figure CN118902995A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of medical technology, and in particular to a sodium hyaluronate injection with cell repair function, a preparation method and application thereof. Background Art
[0002] The skin of the human body will age due to the combined effects of internal and external factors. With the occurrence of aging, changes also occur inside the skin, such as the reduction of extracellular matrix. This is the root cause of skin wrinkling and sagging. Therefore, to solve these problems, we need to start from the root, such as replenishing the extracellular matrix of the skin. The extracellular matrix of the skin contains a variety of high-molecular polysaccharides, such as hyaluronic acid. The structural unit of hyaluronic acid is a disaccharide composed of D-glucuronic acid and N-acetylglucosamine. It exists in most soft connective tissues including the skin and has extremely strong water retention properties. As people age and are affected by environmental factors, the body's ability to synthesize hyaluronic acid gradually decreases, and the content of hyaluronic acid in the skin will gradually decrease. Therefore, replenishing the hyaluronic acid lost by the skin has become an important means of plastic surgery, and a variety of hyaluronic acid injection beauty products have been launched on the market.
[0003] Exogenous aging of the skin, influenced by ultraviolet radiation, is one of the main risk factors for photoaging. Ultraviolet radiation stimulates the production of reactive oxygen species (ROS), which induce oxidative stress and inflammatory responses in the skin, leading to tissue damage.
[0004] In addition, cosmetics used daily may contain some irritating substances or allergenic ingredients, such as alcohol, fruit acid, fragrance and cinnamyl alcohol, which can cause allergic reactions of the skin and lead to skin inflammation.
[0005] In order to reduce and prevent skin damage caused by ultraviolet radiation or skin inflammation, it is of great significance to develop sodium hyaluronate injection with cell repair function. Summary of the invention
[0006] The purpose of the present invention is to provide a sodium hyaluronate injection with cell repair function, which can replenish water to cells, eliminate skin wrinkles and sagging, and reduce the damage to cells caused by ultraviolet radiation or inflammation.
[0007] The present invention solves the above technical problems through the following technical solutions.
[0008] The invention provides a sodium hyaluronate injection with cell repair function, which consists of sodium hyaluronate, tranexamic acid and phosphate buffer.
[0009] In some embodiments, the phosphate buffer comprises dihydrogen phosphate and / or dihydrogen phosphate, preferably disodium hydrogen phosphate and / or sodium dihydrogen phosphate.
[0010] In some embodiments, the pH of the phosphate buffer is 6-8, preferably pH 6.5-7.5.
[0011] In some embodiments, the osmotic pressure of the phosphate buffer is 100 mOsmol / kg-320 mOsmol / kg, preferably 120 mOsmol / kg-150 mOsmol / kg.
[0012] In some embodiments, the mass ratio of sodium hyaluronate to tranexamic acid in the injection is 0.1-10:1; preferably, the mass ratio of sodium hyaluronate to tranexamic acid is 5:3.
[0013] In some embodiments, the injection contains 1-10 mg / mL sodium hyaluronate and 1-10 mg / mL tranexamic acid; preferably, the injection contains 5 mg / mL sodium hyaluronate and 3 mg / mL tranexamic acid.
[0014] In some embodiments, the weight average molecular weight of the sodium hyaluronate is 800,000-1.1 million Da.
[0015] The present invention also provides a method for preparing a sodium hyaluronate injection having a cell repair function, comprising the following steps: preparing a phosphate buffer solution; sequentially adding sodium hyaluronate and tranexamic acid, mixing, and sterilizing with wet heat;
[0016] Furthermore, the steps are specifically as follows:
[0017] (1) Weighing dihydrogen phosphate and / or dihydrogen phosphate, dissolving them in water for injection, to prepare a phosphate buffer, wherein the pH of the phosphate buffer is 6-8, and the osmotic pressure is 100 mOsmol / kg-320 mOsmol / kg;
[0018] (2) Add the required amount of sodium hyaluronate to the above phosphate buffer, mix well, then add the required amount of tranexamic acid, stir until completely dissolved, filter, and sterilize the resulting filtrate at 110-130° C. with wet heat for 8-30 min.
[0019] The present invention also provides a sodium hyaluronate injection with cell repair function for use as an injectable filler, characterized in that the injection has a cell repair function; further, the injection can reduce the damage of ultraviolet radiation to cells and promote the repair of inflammatory cells.
[0020] In some embodiments, the injection site is selected from the face, neck, or any one or a combination thereof, preferably the face; optionally, the injection solution is used in combination with an anesthetic.
[0021] In some embodiments, the anesthetic is selected from any one of lidocaine, procaine, tetracaine, bupivacaine, ropivacaine, diclofenac, morphine, hydrocodone, oxycodone, codeine, fentanyl, sodium pentobarbital, sodium phenobarbital, sodium thiopental, chloralose, ethyl carbamate, and chloral hydrate, or a combination thereof.
[0022] On the basis of being in accordance with the common sense in the art, the above-mentioned preferred conditions can be arbitrarily combined to obtain the preferred embodiments of the present application.
[0023] The reagents and raw materials used in the present invention are commercially available.
[0024] The positive and progressive effects of the present invention are:
[0025] The sodium hyaluronate injection of the present invention contains sodium hyaluronate and tranexamic acid. Compared with the injection containing only sodium hyaluronate, it can synergistically resist ultraviolet-induced skin photoaging and promote the repair of damaged cells, thereby reducing the damage of ultraviolet radiation to cells and promoting the repair of inflammatory cells while replenishing water to cells. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The absorbance of cell viability of different groups of photoaging model after 24h of culture;
[0027] Figure 2 The absorbance of cell viability of different groups of photoaging model after 48h of culture;
[0028] Figure 3 The absorbance of cell viability in different groups of SDS injury model after 24 h of culture;
[0029] Figure 4 The absorbance of cell viability in different groups of SDS injury model after 48 hours of culture. DETAILED DESCRIPTION
[0030] The present application is further described below by way of examples, but the present application is not limited to the scope of the examples. The experimental methods without specific conditions in the following examples are selected according to conventional methods and conditions, or according to the product instructions.
[0031] The reagents and raw materials used in the following examples are all commercially available, and the purity of the reagents used is injection grade.
[0032] Example 1
[0033] Injection formula: sodium hyaluronate (5 mg / mL), tranexamic acid (3 mg / mL), and the rest is phosphate buffer.
[0034] The preparation of the above formulation comprises the following steps:
[0035] 1) Weigh 3 g of sodium dihydrogen phosphate monohydrate and 11 g of disodium hydrogen phosphate dodecahydrate, dissolve them in 900 mL of water for injection, transfer to a 1 L volumetric flask, and dilute to 1 L to prepare a phosphate buffer. The pH of the phosphate buffer was measured to be 7.2, and the osmotic pressure was 140 mOsmol / kg.
[0036] 2) Prepare 1L of sample according to the above formula: add the required amount of sodium hyaluronate to the above 900mL phosphate buffer, stir for 1.5-2h at 400-500 rpm, mix thoroughly, then add the required amount of tranexamic acid, stir until completely dissolved, transfer to a 1L volumetric flask, make up to 1L with the above phosphate buffer, filter, and sterilize the filtrate at 121°C for 15min.
[0037] The weight average molecular weight of sodium hyaluronate in the sample was determined to be 910,000.
[0038] Comparative Example 1
[0039] Injection formula: sodium hyaluronate (5 mg / mL), the rest is phosphate buffer.
[0040] The preparation of the above formulation is compared with that of Example 1, except that the step of adding tranexamic acid is missing, and other conditions and parameters are the same as those of Example 1.
[0041] Example 2
[0042] Photoaging model cell experiment
[0043] 2.1 The samples of Comparative Example 1 and Example 1 were respectively extracted using DMEM complete medium at 0.2 g / mL.
[0044] 2.2 Human fibroblasts were cultured at a rate of 1×10 5 The cells were plated in a 96-well plate at a density of 100 / well and placed in an incubator for 24 h; the 96-well plate culture medium was discarded, and 100 uL PBS was added to each well; an ultraviolet lamp was placed 10 cm above the cell culture dish and irradiated for 30 min; PBS was discarded, and then the cells were divided into a comparative example 1 group and an example 1 group, and the comparative example 1 sample extracted with DMEM complete culture medium and the example 1 sample extracted with DMEM complete culture medium were added respectively; after culturing for 24 h and 48 h, the cell viability of each group was detected using the CCK8 method.
[0045] 2.3 Analysis of experimental results of photoaging cells
[0046] Table 1 shows the cell proliferation activity data of different groups of photoaging cell models after 24h and 48h of culture. Figure 1 and Figure 2The absorbance of cell viability of different groups after 24h and 48h of culture. It can be seen from Table 1 that the cell viability of Example 1 group (Example-2) increased by 5.29% at 24h and 22.62% at 48h compared with the comparative example 1 group (Example-1), and p<0.05, which is significantly different. At the same time, it was found that the cell viability of the comparative example 1 group (Example-1) in the photoaging model decreased with time, and the survival rate of the comparative example 1 group (Example-1) decreased from 90.78% to 76.43%; while the cell viability of the example 1 group (Example-2) in the photoaging model increased with time, and the survival rate of the example 1 group (Example-2) increased from 96.07% to 99.05%.
[0047] Table 1 Cell proliferation activity data of photoaging model cultured for 24h and 48h
[0048]
[0049] Example 3
[0050] Sodium dodecyl sulfate (SDS) is a common surfactant. High concentrations of SDS can cause short-term and long-term damage to the skin barrier, continuously stimulate and destroy the cell membrane of skin cells, increase cell stress, induce cells to secrete free radicals, and activate the release of related inflammatory factors, including TNFα, IL-1α and other types of interleukins, leading to increased inflammatory response and erythema. An in vitro two-dimensional cell injury model was established based on human fibroblasts to simulate the inflammatory environment of wound cells when the skin is damaged, and to evaluate the repair effect of different biomaterials on epidermal cells in an inflammatory state. The repair effect of the materials on epidermal cells in a damaged state was evaluated by detecting cell viability.
[0051] SDS cell damage experiment
[0052] 3.1 The samples of Comparative Example 1 and Example 1 were respectively extracted using DMEM complete medium at 0.2 g / mL.
[0053] 3.2 Human fibroblasts were cultured at a rate of 1×10 5 The cells were plated in a 96-well plate at a density of 1000 μg / well and placed in an incubator for 24 h, and the 96-well plate culture medium was discarded; DMEM culture medium containing 50 μg / mL SDS and 4% serum was added to each well; after 2 h of injury, the supernatant was discarded and the cells were washed twice with PBS; PBS was discarded, and then the cells were divided into a comparative example 1 group and an example 1 group, and the comparative example 1 sample extracted with DMEM complete culture medium and the example 1 sample extracted with DMEM complete culture medium were added respectively; after culturing for 24 h and 48 h, the cell viability of each group was detected using the CCK8 method.
[0054] 3.3 Analysis of SDS cell injury experiment results
[0055] Table 2 shows the cell proliferation activity data of different groups in the SDS cell injury model cultured for 24h and 48h. Figure 3 and Figure 4 The absorbance of cell viability of different groups after 24h and 48h of culture is shown in Table 2. Compared with the comparative example 1 group (Example-1), the cell viability of Example 1 group (Example-2) did not increase at 24h, but increased by 7.19% at 48h, which is a significant difference. At the same time, it was found that the cell viability of Example 1 group and the comparative example 1 group (Example-1) in the SDS cell injury model increased with time, and the cell viability increased from 95.37% to 110.53% and from 97.25% to 103.34%, respectively.
[0056] Table 2 Cell proliferation activity data of SDS injury model cultured for 24h and 48h
[0057]
[0058] Finally, it should be noted that in this application, the terms "comprises", "includes" or any other variations thereof are intended to cover non-exclusive inclusion, so that a process, method, article or apparatus that includes a series of elements includes not only those elements, but also other elements that are not explicitly listed, or also includes elements that are inherent to such process, method, article or apparatus.
[0059] Although the present application has been disclosed above through the description of the specific embodiments of the present application, it should be understood that those skilled in the art can design various modifications, improvements or equivalents to the present application within the spirit and scope of the attached scheme. These modifications, improvements or equivalents should also be considered to be included in the scope of protection claimed in the present application.
Claims
1. A sodium hyaluronate injection with cell repair function, It is characterized in that It is composed of sodium hyaluronate, tranexamic acid and phosphate buffer.
2. The sodium hyaluronate injection according to claim 1, It is characterized in that The phosphate buffer comprises dihydrogen phosphate and / or dihydrogen phosphate, preferably disodium hydrogen phosphate and / or sodium dihydrogen phosphate.
3. The sodium hyaluronate injection according to claim 2, It is characterized in that The pH of the phosphate buffer is 6-8, preferably 6.5-7.
5.
4. The sodium hyaluronate injection according to claim 3, It is characterized in that The osmotic pressure of the phosphate buffer is 100 mOsmol / kg-320 mOsmol / kg, preferably 120 mOsmol / kg-150 mOsmol / kg.
5. The sodium hyaluronate injection according to claim 4, It is characterized in that The mass ratio of sodium hyaluronate to tranexamic acid in the injection is 0.1-10:1; preferably, the mass ratio of sodium hyaluronate to tranexamic acid is 5:
3.
6. The sodium hyaluronate injection according to claim 5, It is characterized in that The injection solution contains 1-10 mg / mL of sodium hyaluronate and 1-10 mg / mL of tranexamic acid; preferably, the injection solution contains 5 mg / mL of sodium hyaluronate and 3 mg / mL of tranexamic acid.
7. The sodium hyaluronate injection according to claim 6, It is characterized in that The weight average molecular weight of the sodium hyaluronate is 800,000-1.1 million Da.
8. A method for preparing the sodium hyaluronate injection according to any one of claims 1 to 7, It is characterized in that The method comprises the following steps: preparing a phosphate buffer solution; sequentially adding sodium hyaluronate and tranexamic acid, mixing well, and sterilizing by wet heat; Furthermore, the steps are specifically as follows: (1) Weighing dihydrogen phosphate and / or dihydrogen phosphate, dissolving them in water for injection, to prepare a phosphate buffer, wherein the pH of the phosphate buffer is 6-8, and the osmotic pressure is 100 mOsmol / kg-320 mOsmol / kg; (2) Add the required amount of sodium hyaluronate to the above phosphate buffer, mix well, then add the required amount of tranexamic acid, stir until completely dissolved, filter, and sterilize the resulting filtrate at 110-130° C. with wet heat for 8-30 min.
9. Use of the sodium hyaluronate injection according to any one of claims 1 to 7 as an injectable filler, It is characterized in that The injection has a cell repair function; further, the injection can reduce the damage of ultraviolet radiation to cells and promote the repair of inflammatory cells.
10. The use according to claim 9, It is characterized in that The injection site is selected from the face, neck, or any one or a combination thereof, preferably the face; optionally, the injection solution is used in combination with an anesthetic.
